Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Hong Kong · Delayed Price · Currency is HKD 22.54
+1.34 (6.32%)
At close: Mar 27, 2026
HKG:1877 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,462 | 1,876 | 1,474 | 1,453 | 3,768 |
Other Revenue | 36.19 | 72.73 | 28.4 | - | 257.09 |
| 2,498 | 1,948 | 1,503 | 1,453 | 4,025 | |
Revenue Growth (YoY) | 28.23% | 29.67% | 3.38% | -63.89% | 152.36% |
Cost of Revenue | 530.98 | 523.54 | 634.39 | 526.28 | 1,258 |
Gross Profit | 1,967 | 1,425 | 868.16 | 927.21 | 2,767 |
Selling, General & Admin | 1,547 | 1,508 | 1,381 | 1,294 | 1,377 |
Research & Development | 1,342 | 1,275 | 1,937 | 2,384 | 2,069 |
Other Operating Expenses | -5.45 | 10.35 | 7.54 | 11.75 | 7.07 |
Operating Expenses | 2,881 | 2,779 | 3,344 | 3,690 | 3,453 |
Operating Income | -913.6 | -1,354 | -2,476 | -2,763 | -686.06 |
Interest Expense | -74.77 | -51.35 | -29.01 | -29.37 | -21.83 |
Interest & Investment Income | 31.88 | 43.63 | 173.42 | 61.02 | 30.98 |
Earnings From Equity Investments | - | - | - | -71.03 | - |
Currency Exchange Gain (Loss) | -21.68 | 8.27 | -2.66 | -50.05 | -39.94 |
Other Non Operating Income (Expenses) | 7.82 | 11.53 | -38.71 | 117.42 | 0.13 |
EBT Excluding Unusual Items | -970.35 | -1,342 | -2,373 | -2,735 | -716.72 |
Gain (Loss) on Sale of Investments | -49.21 | -71.23 | -149.18 | - | 65.75 |
Gain (Loss) on Sale of Assets | 35.26 | 12.78 | 28.89 | 27.01 | 0.78 |
Asset Writedown | -42.02 | -0.94 | - | - | - |
Other Unusual Items | 3.04 | 43.68 | 1.55 | 32.74 | 55.2 |
Pretax Income | -1,023 | -1,358 | -2,492 | -2,675 | -595 |
Income Tax Expense | -13.88 | 22.55 | 43.99 | -93.11 | 135.53 |
Earnings From Continuing Operations | -1,009 | -1,380 | -2,536 | -2,582 | -730.53 |
Net Income to Company | -1,009 | -1,380 | -2,536 | -2,582 | -730.53 |
Minority Interest in Earnings | 134.22 | 99.18 | 252.26 | 196.03 | 9.62 |
Net Income | -875.17 | -1,281 | -2,283 | -2,386 | -720.91 |
Net Income to Common | -875.17 | -1,281 | -2,283 | -2,386 | -720.91 |
Shares Outstanding (Basic) | 1,006 | 985 | 984 | 917 | 890 |
Shares Outstanding (Diluted) | 1,006 | 985 | 984 | 917 | 890 |
Shares Change (YoY) | 2.09% | 0.11% | 7.28% | 3.08% | 8.28% |
EPS (Basic) | -0.87 | -1.30 | -2.32 | -2.60 | -0.81 |
EPS (Diluted) | -0.87 | -1.30 | -2.32 | -2.60 | -0.81 |
Free Cash Flow | -1,288 | -2,125 | -2,838 | -2,158 | -1,507 |
Free Cash Flow Per Share | -1.28 | -2.16 | -2.88 | -2.35 | -1.69 |
Gross Margin | 78.75% | 73.13% | 57.78% | 63.79% | 68.74% |
Operating Margin | -36.57% | -69.49% | -164.79% | -190.09% | -17.05% |
Profit Margin | -35.03% | -65.75% | -151.97% | -164.16% | -17.91% |
Free Cash Flow Margin | -51.55% | -109.06% | -188.85% | -148.50% | -37.44% |
EBITDA | -652.25 | -1,077 | -2,204 | -2,520 | -476.32 |
EBITDA Margin | -26.11% | -55.30% | -146.66% | -173.40% | -11.83% |
D&A For EBITDA | 261.35 | 276.56 | 272.32 | 242.54 | 209.74 |
EBIT | -913.6 | -1,354 | -2,476 | -2,763 | -686.06 |
EBIT Margin | -36.57% | -69.49% | -164.79% | -190.09% | -17.04% |
Revenue as Reported | 2,498 | 1,948 | 1,503 | - | 4,025 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.